Pembrolizumab plus chemotherapy with or without bevacizumab led to a substantial improvement in overall survival vs placebo plus chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer, according to the final OS analysis of the KEYNOTE-826 trial.